Development and validation of a severity scale for leprosy type 1 reactions
- PMID: 19104651
- PMCID: PMC2596969
- DOI: 10.1371/journal.pntd.0000351
Development and validation of a severity scale for leprosy type 1 reactions
Abstract
Objectives: To develop a valid and reliable quantitative measure of leprosy Type 1 reactions.
Methods: A scale was developed from previous scales which had not been validated. The face and content validity were assessed following consultation with recognised experts in the field. The construct validity was determined by applying the scale to patients in Bangladesh and Brazil who had been diagnosed with leprosy Type 1 reaction. An expert categorized each patient's reaction as mild or moderate or severe. Another worker applied the scale. This was done independently. In a subsequent stage of the study the agreement between two observers was assessed.
Results: The scale had good internal consistency demonstrated by a Cronbach's alpha >0.8. Removal of three items from the original scale resulted in better discrimination between disease severity categories. Cut off points for Type 1 reaction severities were determined using Receiver Operating Characteristic curves. A mild Type 1 reaction is characterized using the final scale by a score of 4 or less. A moderate reaction is a score of between 4.5 and 8.5. A severe reaction is a score of 9 or more.
Conclusions: We have developed a valid and reliable tool for quantifying leprosy Type 1 reaction severity and believe this will be a useful tool in research of this condition, in observational and intervention studies, and in the comparison of clinical and laboratory parameters.
Conflict of interest statement
The authors have declared that no competing interests exist.
Figures




Similar articles
-
A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale.PLoS Negl Trop Dis. 2017 Jul 3;11(7):e0005716. doi: 10.1371/journal.pntd.0005716. eCollection 2017 Jul. PLoS Negl Trop Dis. 2017. PMID: 28671966 Free PMC article.
-
Development and validation of a scale to assess attitudes of health care providers towards persons affected by leprosy in southern India.PLoS Negl Trop Dis. 2018 Sep 25;12(9):e0006808. doi: 10.1371/journal.pntd.0006808. eCollection 2018 Sep. PLoS Negl Trop Dis. 2018. PMID: 30252851 Free PMC article.
-
Validation of the questionnaire on hand function assessment in leprosy.Rev Saude Publica. 2012 Jun;46(3):435-45. doi: 10.1590/s0034-89102012000300005. Rev Saude Publica. 2012. PMID: 22635035 English, Portuguese.
-
The usefulness of terminal latency index of median nerve and f-wave difference between median and ulnar nerves in assessing the severity of carpal tunnel syndrome.J Clin Neurophysiol. 2014 Apr;31(2):162-8. doi: 10.1097/WNP.0000000000000041. J Clin Neurophysiol. 2014. PMID: 24691235
-
A comparison of the change in clinical severity scale score and a retrospective physician assessment of neurological outcome in individuals with leprosy associated nerve function impairment after treatment with corticosteroids.Lepr Rev. 2012 Jun;83(2):154-63. Lepr Rev. 2012. PMID: 22997691 Clinical Trial.
Cited by
-
Analysis of therapeutic effectiveness and adverse effects of long-term corticosteroids among leprosy patients with reactions: A retrospective cohort study.SAGE Open Med. 2022 Apr 19;10:20503121221089448. doi: 10.1177/20503121221089448. eCollection 2022. SAGE Open Med. 2022. PMID: 35465634 Free PMC article.
-
Two randomized controlled clinical trials to study the effectiveness of prednisolone treatment in preventing and restoring clinical nerve function loss in leprosy: the TENLEP study protocols.BMC Neurol. 2012 Dec 18;12:159. doi: 10.1186/1471-2377-12-159. BMC Neurol. 2012. PMID: 23249098 Free PMC article. Clinical Trial.
-
Whole blood RNA signatures in leprosy patients identify reversal reactions before clinical onset: a prospective, multicenter study.Sci Rep. 2019 Nov 29;9(1):17931. doi: 10.1038/s41598-019-54213-y. Sci Rep. 2019. PMID: 31784594 Free PMC article.
-
Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial.PLoS Negl Trop Dis. 2017 Oct 4;11(10):e0005952. doi: 10.1371/journal.pntd.0005952. eCollection 2017 Oct. PLoS Negl Trop Dis. 2017. PMID: 28976976 Free PMC article. Clinical Trial.
-
Study of Dermal Nerve Pathology in Upgrading and Downgrading Type 1 and Type 2 Leprosy Reactions.Am J Trop Med Hyg. 2025 Feb 25;112(5):1081-1086. doi: 10.4269/ajtmh.23-0426. Print 2025 May 7. Am J Trop Med Hyg. 2025. PMID: 39999455
References
-
- Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec. 2008;83:293–300. - PubMed
-
- Ridley DS, Jopling WH. Classification of Leprosy according to immunity. Int J Lepr Other Mycobact Dis. 1966;34:255–273. - PubMed
-
- Modlin RL. Th1-Th2 paradigm: insights from leprosy. J Invest Dermatol. 1994;102:828–832. - PubMed
-
- van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev. 2005;76:14–34. - PubMed
-
- Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, et al. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis. 2007;44:33–40. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical